Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Alere Receives FDA Clearance for Alere™ i Influenza A & B 2 Rapid Molecular Test Latest testing application on innovative Alere i molecular diagnostic platform detects influenza infections in...
Alere Announces the U.S. Department of Justice Closes Investigation PR Newswire WALTHAM, Mass., Sept. 29, 2017 WALTHAM, Mass., Sept. 29, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the...
Abbott Acquisition of Alere Set to Close on October 3, 2017 PR Newswire WALTHAM, Mass., Sept. 29, 2017 WALTHAM, Mass., Sept. 29, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) announced today that...
Alere Announces Agreement in Principle to Settle with the U.S. Department of Justice PR Newswire WALTHAM, Mass., Sept. 28, 2017 WALTHAM, Mass., Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (NYSE:...
Alere Announces Settlement with SEC PR Newswire WALTHAM, Mass., Sept. 28, 2017 WALTHAM, Mass., Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid...
Alere Announces Intent to Voluntarily Delist Series B Convertible Perpetual Preferred Stock from the NYSE Conditioned Upon the Completion of its Acquisition by Abbott PR Newswire WALTHAM, Mass...
Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock PR Newswire WALTHAM, Mass., Sept. 18, 2017 WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ -- Alere Inc. (NYSE:...
Alere Provides Notice to Holders of Series B Convertible Perpetual Preferred Stock PR Newswire WALTHAM, Mass., Aug. 11, 2017 WALTHAM, Mass., Aug. 11, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR...
Alere Reports Second Quarter 2017 Financial Results PR Newswire WALTHAM, Mass., Aug. 3, 2017 WALTHAM, Mass., Aug. 3, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid...
Immunalysis Receives FDA Clearance for SEFRIA™ Fentanyl Urine Drug Screening Test First-ever 510(k)-cleared fentanyl enzyme immunoassay brings high-performance qualitative screening to a wide...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
